In silico studies shows that berberine interacts with key oncogenic proteins such as p53, EGFR, AKT, p38, and ERK1/2, while in vitro experiments validated its ability to decrease the phosphorylation of these proteins, highlighting its potential as an effective treatment for oral squamous cell carcinoma and breast cancer [196, 197]. Here, TP53 is linked to breast carcinoma.